{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:44:36Z","timestamp":1789980276094,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jagiellonian University Medical Collage","award":["K\/DSC\/001953"],"award-info":[{"award-number":["K\/DSC\/001953"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11011-017-0175-1","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T23:15:52Z","timestamp":1514934952000},"page":"733-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating"],"prefix":"10.1007","volume":"33","author":[{"given":"Magdalena","family":"Kota\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Lustyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bucki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Marcinkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"\u015aniecikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"175_CR1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1017\/S1461145710000659","volume":"13","author":"J Arnt","year":"2010","unstructured":"Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW et al (2010) LuAE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 13:1021\u20131033. \nhttps:\/\/doi.org\/10.1017\/S1461145710000659","journal-title":"Int J Neuropsychopharmacol"},{"key":"175_CR2","doi-asserted-by":"crossref","first-page":"PL113","DOI":"10.1016\/S0024-3205(98)00322-1","volume":"63","author":"G Colombo","year":"1998","unstructured":"Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113\u2013PL117","journal-title":"Life Sci"},{"key":"175_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s11011-015-9736-3","volume":"30","author":"M Dudek","year":"2015","unstructured":"Dudek M, Marcinkowska M, Bucki A, Olczyk A, Ko\u0142aczkowski M (2015) Idalopirdine \u2013 a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis 30:1487\u20131494. \nhttps:\/\/doi.org\/10.1007\/s11011-015-9736-3","journal-title":"Metab Brain Dis"},{"issue":"7","key":"175_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1517\/13543784.2015.1052402","volume":"24","author":"D Galimberti","year":"2015","unstructured":"Galimberti D, Scarpini E (2015) Idalopirdine as a treatment for Alzheimer's disease. Expert Opin Investig Drugs 24(7):981\u2013987. \nhttps:\/\/doi.org\/10.1517\/13543784.2015.1052402","journal-title":"Expert Opin Investig Drugs"},{"key":"175_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.pharmthera.2007.08.006","volume":"117","author":"DJ Heal","year":"2008","unstructured":"Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H (2008) Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 117:207\u2013231. \nhttps:\/\/doi.org\/10.1016\/j.pharmthera.2007.08.006","journal-title":"Pharmacol Ther"},{"key":"175_CR6","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/sj.bjp.0701312","volume":"121","author":"HC Jackson","year":"1997","unstructured":"Jackson HC, Needham AM, Hutchins LJ, Mazurkiewicz SE, Heal DJ (1997) Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br J Pharmacol 121:1758\u20131762. \nhttps:\/\/doi.org\/10.1038\/sj.bjp.0701312","journal-title":"Br J Pharmacol"},{"key":"175_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fnins.2017.00050","volume":"11","author":"M Kota\u0144ska","year":"2017","unstructured":"Kota\u0144ska M, \u015aniecikowska J, Jastrz\u0119bska-Wi\u0119sek M, Ko\u0142aczkowski M, Pytka K (2017) Metabolic and cardiovascular benefits and risks of EMD386088 - a 5-HT6 receptor partial agonist and dopamine transporter inhibitor. Front Neurosci 11:50. \nhttps:\/\/doi.org\/10.3389\/fnins.2017.00050\n\n eCollection 2017 Feb 8","journal-title":"Front Neurosci"},{"key":"175_CR8","doi-asserted-by":"publisher","unstructured":"M\u00f8rk A, Russell RV, de Jong IE, Smagin G (2017) Effects of the 5-HT6 receptor antagonist idalopirdine on extracellular levels of monoamines, glutamate and acetylcholine in the rat medial prefrontal cortex. Eur J Pharmacol 799:1\u20136. \nhttps:\/\/doi.org\/10.1016\/j.ejphar.2017.02.010","DOI":"10.1016\/j.ejphar.2017.02.010"},{"key":"175_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00442252","volume":"97","author":"JC Neill","year":"1989","unstructured":"Neill JC, Cooper SJ (1989) Evidence that d-fenfluramine anorexia is mediated by 5-HT1 receptors. Psychopharmacology 97:213\u2013218. \nhttps:\/\/doi.org\/10.1007\/BF00442252","journal-title":"Psychopharmacology"},{"key":"175_CR10","unstructured":"Pasternak A, Szymonifka MJ (2009) Tryptamine sulfonamides as 5-ht6 antagonists. WO2009073118 A1"},{"key":"175_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nut.2016.10.017","volume":"36","author":"I Rutigliano","year":"2017","unstructured":"Rutigliano I, Vinci R, De Filippo G, Mancini M, Stoppino L, d\u2019apolito M, Giardino I, Macarini L, Mantovani MP, Campanozzi A (2017) Metabolic syndrome, hepatic steatosis, and cardiovascular risk in children. Nutrition 36:1\u20137. \nhttps:\/\/doi.org\/10.1016\/j.nut.2016.10.017","journal-title":"Nutrition"},{"key":"175_CR12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2011.01.005","volume":"1","author":"BJ Sargent","year":"2011","unstructured":"Sargent BJ, Henderson AJ (2011) Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol 1:52\u201358","journal-title":"Curr Opin Pharmacol"},{"key":"175_CR13","doi-asserted-by":"crossref","unstructured":"Smith BM, Smith JM, Tsai JH, Schultz JA, Gilson CA, Estrada SA et al (2008) Discovery and structure-activity relationship of (1R)-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem 51:305\u2013313","DOI":"10.1021\/jm0709034"},{"key":"175_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0091-3057(93)90126-E","volume":"45","author":"N Takeda","year":"1993","unstructured":"Takeda N, Hasegawa S, Morita M, Matsunaga T (1993) Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav 45:817\u2013821. \nhttps:\/\/doi.org\/10.1016\/0091-3057(93)90126-E","journal-title":"Pharmacol Biochem Behav"},{"key":"175_CR15","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/j.1476-5381.2011.01245.x","volume":"164","author":"SP Vickers","year":"2011","unstructured":"Vickers SP, Jackson HC, Cheetham SC (2011) The utiliry of animal models to evaluate novel anti-obesity agents. Br J Pharmacol 164:1248\u20131262. \nhttps:\/\/doi.org\/10.1111\/j.1476-5381.2011.01245.x","journal-title":"Br J Pharmacol"},{"key":"175_CR16","unstructured":"WHO (2015) Childhood overweight and obesity. \nhttp:\/\/www.who.int\/dietphysicalactivity\/childhood\/en\/"},{"key":"175_CR17","doi-asserted-by":"publisher","unstructured":"Wilkinson D, Windfeld K, Colding-J\u00f8rgensen E (2014) Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): a randomized, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 13:1092\u20131099. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(14)70198-X","DOI":"10.1016\/S1474-4422(14)70198-X"},{"key":"175_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1358\/mf.2002.24.3.802297","volume":"24","author":"K Yamamoto","year":"2002","unstructured":"Yamamoto K, Matsunaga S, Matsui M, Takeda N, Yamatodani A (2002) Pica in mice as a new model for the study of emesis. Methods Find Exp Clin Pharmacol 24:135\u2013138. \nhttps:\/\/doi.org\/10.1358\/mf.2002.24.3.802297","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"175_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000212758","volume":"55","author":"M Zeyda","year":"2009","unstructured":"Zeyda M, Stulnig TM (2009) Obesity, inflammation, and insulin resistance \u2013 a mini-review. Gerontology 55:379\u2013386. \nhttps:\/\/doi.org\/10.1159\/000212758","journal-title":"Gerontology"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-017-0175-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-0175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-017-0175-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T06:09:32Z","timestamp":1526450972000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-017-0175-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s11011-017-0175-1","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}